

September 22, 2011

AnGes MG, Inc.

**The Developmental Status of Anticancer Drug, HVJ-E (GEN0101/TSD-0014)
by GenomIdea, a Subsidiary of AnGes MG**

A subsidiary of AnGes MG Inc., GenomIdea, Inc. (hereinafter called “GenomIdea”) presented the developmental status of a novel anticancer drug, HVJ-E (GEN0101/TSD-0014) at “life science industry meeting to develop a network and to exchange information between companies in eastern and western Japan” hosted by Senri Life Science Foundation on September, 8.

Currently, Osaka University Hospital is conducting investigator-initiated clinical trials on HVJ-E (GEN0101/TSD-0014) for 2 types of cancer, namely advanced malignant melanoma and castration-resistant prostate cancer. Meanwhile, GenomIdea is preparing for an industry-sponsored clinical trial for the indication of castration-resistant prostate cancer. The detailed information on these clinical trials can be found at University hospital Medical Information Network (UMIN) website below:

Advanced malignant melanoma:

<https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&rcptno=R000002889&language=E>

Castration-resistant prostate cancer:

<https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&rcptno=R000007153&language=E>

The study group conducting investigator-initiated clinical trials at Osaka University has analysed mode of actions of HVJ-E and revealed its unique cancer-killing mechanism mediated by an intracellular nucleic acid receptor (RIG-I) signal and cancer-specific immunity induced by the activation of dendritic cells.

On the other hand, aiming for development of a new drug for castration-resistant prostate cancer, GenomIdea nearly completed obtaining non clinical data, such as toxicity, pharmacology and stability, which are required in order to start industry-sponsored clinical trials and is currently preparing for a preliminary consultation with the regulatory authority prior to initiation of clinical trial.

This trend will have no effect on the consolidated business performance for the fiscal year of 2011.